Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O00468: Variant p.Val1727Phe

Agrin
Gene: AGRN
Feedback?
Variant information Variant position: help 1727 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Phenylalanine (F) at position 1727 (V1727F, p.Val1727Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMS8; decreased AGRN-induced clustering of AChR by >100-fold and decreased phosphorylation of the MUSK receptor and AChR beta subunit by about 10-fold. Increased binding to alpha-dystroglycan. Any additional useful information about the variant.


Sequence information Variant position: help 1727 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2068 The length of the canonical sequence.
Location on the sequence: help GKGAAVIRSREPVTLGAWTR V SLERNGRKGALRVGDGPRVL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GKGAAVIRSREPVTLGAWTRVSLERNGRKGALRVGDGPRVL

Mouse                         GKGAAIIRSKEPIALGTWVRVFLERNGRKGALQVGDGPRVL

Rat                           GKGAAVIRSKEPIALGTWVRVFLERNGRKGALQVGDGPRVL

Chicken                       GKGAAVLRSKEPVPLNTWISVLLERSGRKGVMRINNGERVM
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 30 – 2068 Agrin
Chain 1103 – 2068 Agrin C-terminal 110 kDa subunit
Chain 1103 – 1863 Agrin C-terminal 90 kDa fragment
Domain 1635 – 1822 Laminin G-like 2



Literature citations
LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.
Maselli R.A.; Fernandez J.M.; Arredondo J.; Navarro C.; Ngo M.; Beeson D.; Cagney O.; Williams D.C.; Wollmann R.L.; Yarov-Yarovoy V.; Ferns M.J.;
Hum. Genet. 131:1123-1135(2012)
Cited for: VARIANT CMS8 PHE-1727; INTERACTION WITH DAG1; CHARACTERIZATION OF VARIANT CMS8 PHE-1727;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.